Iconovo AB specializes in the development of inhaled medicinal products, collaborating with international pharmaceutical companies to create innovative inhalation solutions. The company offers a range of patented dry powder inhaler devices and in-house formulation services, which facilitate the development of both new pharmaceuticals and generic medicines. Iconovo's expertise lies in its integrated development process, combining engineering and pharmaceutical knowledge to optimize inhaler designs and dry powder formulations. This comprehensive approach allows them to support clients throughout the entire product development journey, from initial concept to market-ready inhalation products.

In addition to device development, Iconovo provides advisory services to assist clients in navigating the complexities of inhalation product development. Their offerings include pre-formulation studies to assess the physicochemical properties of active pharmaceutical ingredients (APIs), feasibility studies to evaluate the potential of APIs for inhalation, and clinical trial support tailored to the unique challenges of inhaled products. Iconovo also maintains a network of contract manufacturing organizations (CMOs) to ensure efficient production processes, including the manufacturing and filling of formulations and the assembly of final products. This combination of technical expertise and strategic partnerships positions Iconovo as a key player in the inhalation therapeutics market.

Sweden

Iconovo is a leading Swedish CDMO company, offering innovative and effective inhalation platforms to the international pharmaceutical industry. We have several types of patented dry powder inhalers that can create significant commercial opportunities for the development of both new pharmaceuticals and generic medicine. Our strength is our inhouse capabilities with full control over both device development and formulation, meaning less risk and faster time to market.

Iconovo AB

Company Details